Peloton Therapeutics Scheduled, Nasdaq: PLTX

Phase 2 biotech developing small-molecule HIF-2a inhibitors for kidney cancer.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a clinical stage biopharmaceutical company focused on translating novel scientific insights into first-in-class medicines for patients with cancer and other debilitating or life-threatening conditions. We are initially targeting HIF-2a, a transcription factor which was previously thought to be intractable using a small molecule. We are a leader in the field of HIF-2a biology and pioneered the first HIF-2a inhibitor drug candidate to enter into clinical development. Our lead drug candidate, PT2977, has shown clinical proof of concept in patients with mRCC, and we plan to initiate patient enrollment in an international Phase 3 clinical trial in previously treated mRCC patients in the second half of 2019. PT2977 is also in a Phase 2 clinical trial in patients with VHL disease-associated RCC in the United States and Europe. VHL disease is a familial cancer syndrome that commonly gives rise to renal cell tumors. There are currently no approved drugs for VHL disease, and we intend to seek orphan drug designation for PT2977 in this indication. We also have another HIF-2a inhibitor drug candidate, PT2567, in preclinical development for non-oncology indications.
more less
IPO News for Peloton Therapeutics
more
IPO Data
IPO File Date 04/26/2019
Offer Price
Price Range $15.00 - $17.00
Offer Shares (mm) 9.4
Deal Size ($mm) $150
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $15.00 - $17.00
Offer Shares (mm) 9.4
Deal Size ($mm) $150
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Dallas, TX
Founded 2010
Employees 64
Website www.pelotontherapeutics.com